DUBLIN--(BUSINESS WIRE)--
Research and Markets has announced the addition of the "Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016" report to their offering.
The report provides comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/vw6fr7/integrin_alpha_4

View source version on businesswire.com: http://www.businesswire.com/news/home/20161209005404/en/